Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688956 | 0.93 | ESR1 (0.49) | ESR1HTTAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL2562811 | 0.78 | ACHE (0.48) | ESR1HTTLMNAHPGDMAPK1 | |
| SCHEMBL29372751 | 0.78 | ACHE (0.48) | ESR1HTTLMNAHPGDMAPK1 | |
| SCHEMBL70458 | 0.78 | ACHE (0.48) | ESR1HTTLMNAHPGDMAPK1 | |
| SCHEMBL30367452 | 0.76 | ESR1 (0.47) | ESR1PTGS1PTGS2LMNANPSR1 | |
| SCHEMBL689246 | 0.76 | ESR1 (0.47) | ESR1PTGS1PTGS2LMNANPSR1 | |
| SCHEMBL25330542 | 0.76 | ESR1 (0.41) | ESR1HTTLMNANPC1HPGD | |
| Methoxymethane SCHEMBL7620185 | 0.76 | CYP3A4 (0.46) | ESR1PTGS1PTGS2HTTLMNA | |
| Propionic Acid SCHEMBL29187701 | 0.72 | FFAR3 (0.40) | ESR1PTGS1HTTLMNANPC1 | |
| Butyric Acid SCHEMBL29187703 | 0.71 | FFAR3 (0.46) | ESR1TSHRHTTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2052719-B1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LAB INC (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2110127-B1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LAB INC (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7847132-B2 | Hepatic fibrosis inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20100184858-A1 | Hepatic fibrosis inhibitor | BIOTOXTECH CO., LTD (KR) | 2010-07-22 | — | — | US | disclosed |
| US-20100160432-A1 | Curative drug for neurodegenerative diseases | SUGIYAMA SATORU | 2010-06-24 | — | — | US | disclosed |
| US-20090270654-A1 | HEPATIC FIBROSIS INHIBITOR | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2110127-A1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-10-21 | — | — | EP | disclosed |
| EP-2052719-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20090105339-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184858-A1 | Hepatic fibrosis inhibitor | HDGF, HAVCR2, FABP1 | ESR1 4553/4885TSHR 3929/4885PTGS1 68/4885 |
| US-20090105339-A1 | Curative drug for neurodegenerative diseases | HTT, SNCA, NQO1 | ESR1 4628/4885TSHR 4691/4885PTGS1 986/4885 |
| US-20100160432-A1 | Curative drug for neurodegenerative diseases | HTT, SNCA, NQO1 | ESR1 4628/4885TSHR 4691/4885PTGS1 986/4885 |
| US-20090270654-A1 | HEPATIC FIBROSIS INHIBITOR | HDGF, HAVCR2, FABP1 | ESR1 4553/4885TSHR 3929/4885PTGS1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.